[1] Kawiak A. Molecular Research and Treatment of Breast Cancer. Int J Mol Sci. 2022;23(17):9617. Published 2022 Aug 25. doi:10.3390/ijms23179617 [2] Jerzak KJ, Bouganim N, Brezden-Masley C, et al. HR+/HER2- Advanced Breast Cancer Treatment in the First-Line Setting: Expert Revie...
RIGHT Choice是首个针对侵袭性HR+/HER2-转移性乳腺癌包括内脏危象患者的随机II期临床研究,纳入了222例既往未接受过系统性治疗的绝经前/围绝经期HR+/HER2-、疾病更具侵袭性特点(包括有症状的内脏转移、快速进展、症状性非内脏疾病)的晚期乳腺癌女性患者,按1:1的比例随机分配至瑞波西利联合内分泌治疗和戈舍瑞林组或...
they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data
7. Park, Yeon Hee, et al. "Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, ...
在2024 年的 ASCO 大会中,多项摘要文章报道了 HR+/HER2- 早期乳腺癌患者的复发风险评估或分析结果。 1 Short-term risk of recurrence in patients (pts) with HR+/HER2- early breastcancer (EBC) treated with endocrine therapy (ET) in randomized clinicaltrials (RCTs): A meta-analysis. ...
参考文献: Targeted Agents Expand the HR+/HER2– Metastatic Breast Cancer Treatment Arena.https://www.onclive.com/view/targeted-agents-expand-the-hr-her2-metastatic-breast-cancer-treatment-arena
[4].Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, et al. Firstline treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positivemetastatic breast cancer from registHER. Oncologist 2013;18:501–10.[5].Rimawi M, Ferrero JM, de la ...
大型第三期临床研究发现,HR+ HER2+乳癌患者在完成标准辅助治疗后,以新一代TKI为一年的疗程,配合荷尔蒙药物作为强化延伸辅助治疗(extended adjuvant treatment)可降低复发风险将近一半。」新一代TKI主要副作用是腹泻,但大部分可透过调整剂量和止泻药物有效控制及纾缓,其他严重副作用,例如心脏毒性、皮疹和感染等,发生的机率...
(GCO):Cancer Today[EB/OL]. [2020-04-01].http://gco.iarc.fr/today/home.[3]https://www.targetedonc.com/view/fda-fast-tracks-op-1250-for-hr-her2--metastatic-breast-cancer-treatment[4]张雅聪,吕章艳,宋方方,陈可欣.全球及我国乳腺癌发病和死亡变化趋势[J].肿瘤综合治疗电子杂志,2021,7(02)...
从N+到N0,多因素共筑HR+/HER2-早期乳腺癌风险分层 既往HR+/HER2-早期乳腺癌复发风险的分层依赖于临床病理特征,其中淋巴结状态是影响早期乳腺癌预后最为关键的指标,可以预测短期和长期复发风险3。2017年早期乳腺癌研究者协作组(EBCTCG)报告的一项荟萃分析4表明,淋巴结转移数量越多,患者复发风险越高。其长期随访数据...